Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, Haynes NM.

Cancer Res. 2012 Jul 1;72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210. Epub 2012 May 8.


CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.

Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hämmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ.

J Immunol. 2010 Jul 1;185(1):532-41. doi: 10.4049/jimmunol.0903624. Epub 2010 May 26.


DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.

Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ.

J Immunol. 2010 Jan 15;184(2):902-11. doi: 10.4049/jimmunol.0903225. Epub 2009 Dec 11.


Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Nat Med. 2009 Oct;15(10):1170-8. doi: 10.1038/nm.2028. Epub 2009 Sep 20.


CD1d-based combination therapy eradicates established tumors in mice.

Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ.

J Immunol. 2009 Aug 1;183(3):1911-20. doi: 10.4049/jimmunol.0900796.


Personality dimensions in first-episode psychoses.

Keshavan MS, Duggal HS, Veeragandham G, McLaughlin NM, Montrose DM, Haas GL, Schooler NR.

Am J Psychiatry. 2005 Jan;162(1):102-9.


Supplemental Content

Loading ...
Support Center